

Citi Pharma Limited

February 6, 2025

The General Manager, Pakistan Stock Exchange Limited, Stock Exchange Building, Stock Exchange Road, Karachi.


DECISION OF THE BOARD OF DIRECTORS MEETING

Dear Sir,

We are pleased to inform you that Board of Directors of the Citi Pharma Limited in their meeting held on Thursday, February 6, 2025 at 12:30 P.M. at the Head Office of the Company, has made the following decisions on the agenda items circulated:

SR. NO.	AGENDA ITEM	DECISION OF BOARD / STATUS	
1	Confirmation of the minutes of Board of Directors meeting held on October 29, 2024	Approved	
2	To consider and approve of biological section / plant including separate facilities for different types of Insulin (Regular Insulin, Glargine, Lispro, Aspart, Detemir, Degludec), GLP-1 (Semaglutide and Bio-similar)	Approved	
3	To consider and approval of Carbapenems (Imipenem, Meropenem, Doripenem, Ertapenem) section/ plant	Approved	
4	To consider and approval of Antibiotic plant for formulation section	Approved	
5	To consider the formation of and approval for establishment of Citi REIT Management Company as a wholly owned subsidiary of Citi Pharma Limited and to allow formation of an approval of fund raising for real estate projects.	Approved	
6	To consider and approval to entering into discussions (Stage 3) pertaining to the formation of a Joint Venture with international partners for the development of a hospital	Approved	
7	Any other matter with the permission of the Chair		







Citi Pharma Limited

i)	Discussion on ESG regulatory expectations and disclosures and formation of relevant committees	Under consideration
ii)	To utilize the Hospital proceeds from IPO in establishment of above Pharmaceutical Projects	Approved

You may please inform the TRE Certificate Holders of the Exchange accordingly.







